Veracyte Europe News and Activities

Veracyte Europe is owned by Veracyte.

Veracyte is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Veracyte is a company listed under the stock ticker VCYT (US).

Veracyte has a direct presence in 2 countries.

View the org chart displaying its 6 main executives

Most searched biographies at Veracyte Europe

• Cyril Ransilhac, Senior Director, Operations
• Carmen Ruiz Thous, Senior Medical Affairs Director, Europe, Middle...
• William Bulman, Medical Director, Pulmonology

Popular executive movements at Veracyte

• Tracy Ward has joined the company as Chief Human Resources Officer  (posted on April 12 2026).
• Kevin Haas will join the company as Chief Development and Technology Officer on Mar. 24, 2026  (posted on March 17 2026).

Create your alert
to follow the executive moves at Veracyte Europe.

Veracyte has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Veracyte Europe

• Press Releases | Veracyte, Inc.
• In the News
• Veracyte Completes Acquisition of HalioDx: HalioDx
• HalioDx and Veracyte set proposed acquisition terms: HalioDx
• Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program: HalioDx
• HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil: HalioDx
• Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients: HalioDx
• New data reinforce Immunoscore® clinical utility in localized Colon Cancer: HalioDx
• Transgene - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from Bpifrance’s “Investments for the Future” Programme | SpokeTransgene - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from
• Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio | SpokeTransgene: A Positive 2018, Moving Ahead with a Strong Portfolio
• View more press releases Close

Social media about Veracyte Europe

• Veracyte Europe on Wikipedia, Google News & Yahoo Finance
• Veracyte Europe on LinkedIn, X (Twitter) & YouTube